Lion’s Mane mushroom (Hericium erinaceus) has attracted growing scientific interest not only for its well-documented effects on cognitive function, but also for its potential role in mood regulation. A body of preclinical and clinical research now suggests that this species may support the management of depressive and anxiety-related symptoms through mechanisms distinct from conventional pharmacological approaches. This article reviews the current evidence.
Bioactive Compounds and Their Relevance to Mood
The primary bioactive constituents of Hericium erinaceus are hericenones (found in the fruiting body) and erinacines (found in the mycelium). Both compound classes have been shown in laboratory and animal studies to stimulate the synthesis of nerve growth factor (NGF), a protein critical to the growth, maintenance, and survival of neurons.
NGF plays a significant role in the central nervous system, particularly in regions associated with mood regulation, including the hippocampus. Reduced NGF signaling has been associated with depressive-like behavior in preclinical models. Research suggests that erinacine A-enriched mycelium may also promote hippocampal neurogenesis, a process linked to antidepressant effects in both animal and human research.[1]
Beyond NGF pathways, H. erinaceus bioactive compounds appear to influence brain-derived neurotrophic factor (BDNF) production. BDNF is closely associated with neuroplasticity, and reduced BDNF levels have been observed in individuals with major depressive disorder.
Clinical Evidence for Depression and Anxiety
The Nagano et al. Randomized Controlled Trial (2010)
One of the earliest clinical investigations into H. erinaceus and mood involved a double-blind, placebo-controlled study with 30 female participants over four weeks. Participants in the supplementation group showed significantly lower scores on the Center for Epidemiologic Studies Depression Scale (CES-D) compared to placebo. Measures of anxiety and irritability also trended lower in the supplementation group. The researchers noted that the observed mood effects appeared to involve mechanisms beyond NGF stimulation alone, suggesting additional pathways may be at work.[2]
The Vigna et al. Observational Study (2019)
A clinical trial conducted at IRCCS Foundation Policlinico Hospital in Milan enrolled 77 adults with overweight or obesity who also presented with mood or sleep disorders. After eight weeks of oral H. erinaceus supplementation alongside a low-calorie dietary regimen, participants showed measurable reductions in depression, anxiety, and sleep disturbance scores. Notably, circulating pro-BDNF levels increased following supplementation, though mature BDNF levels did not change significantly. The authors proposed that the pro-BDNF to BDNF ratio may serve as a potential biomarker for tracking H. erinaceus response in future studies.[3]
Proposed Mechanisms of Antidepressant Activity
A 2020 review published in Antioxidants examined the preclinical and clinical evidence for H. erinaceus alongside other herbal compounds with potential antidepressant properties. The authors identified several overlapping mechanisms that may contribute to mood-supporting effects:
- Neurotrophic support: Stimulation of NGF and BDNF synthesis, which may promote neuroplasticity and neuronal repair in mood-related brain regions.
- Neurotransmitter modulation: Preliminary evidence indicates that H. erinaceus extracts may influence serotonergic and dopaminergic signaling, though this evidence remains largely preclinical.
- Anti-inflammatory effects: Chronic low-grade neuroinflammation is increasingly recognized as a contributor to depressive disorders. Bioactive polysaccharides in H. erinaceus may help attenuate inflammatory cytokine activity.
- Oxidative stress reduction: Antioxidant compounds within the mushroom may reduce oxidative burden in the central nervous system, a factor implicated in mood dysregulation.[4]
What a 2025 Systematic Review Found
A systematic review published in Frontiers in Nutrition (2025) assessed the cumulative clinical literature on H. erinaceus supplementation, including five randomized controlled trials and three pilot clinical trials. Across the included studies, the authors found that H. erinaceus was associated with reductions in self-reported symptoms of depression, anxiety, binge eating, and sleep disturbance. The review also noted improvements in hippocampal neurogenesis markers and BDNF-related outcomes in several included studies. The authors concluded that evidence supports a potential role for H. erinaceus in mood dysregulation, while emphasizing the need for larger, longer-duration trials to clarify optimal use.[5]
Limitations of the Current Evidence
The existing clinical literature on H. erinaceus and depression has several notable limitations. Most trials have small sample sizes, relatively short durations, and heterogeneous outcome measures. Several studies have enrolled populations with specific comorbidities (such as obesity or menopausal transition), which limits generalizability. Placebo effects in mood research are well-established, and the blinding adequacy of some published trials is difficult to assess. Additionally, most human trials have not measured bioactive compound concentrations in blood, making it difficult to determine effective exposure levels.
For a deeper look at how Lion’s Mane compounds interact with neural pathways, see our detailed overview of Lion’s Mane, nerve growth factor, hericenones, and erinacines.
Safety Considerations
Across the clinical trials reviewed, H. erinaceus supplementation was generally well-tolerated. Reported adverse effects were infrequent and mild, including occasional gastrointestinal discomfort. A small number of case reports have documented allergic skin reactions in individuals with known mushroom sensitivities. As with any supplement, individuals taking prescription medications, particularly those affecting the central nervous system, should consult a healthcare provider before use.
Summary
Research suggests that Hericium erinaceus may support mood regulation through neurotrophic, anti-inflammatory, and neuroprotective mechanisms. Clinical trials indicate potential benefits for reducing self-reported symptoms of depression and anxiety, though the evidence base remains preliminary. Larger, well-controlled human trials are needed before definitive conclusions can be drawn.
References
- [1] Tsai-Teng T, et al. Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer’s disease-related pathologies in APPswe/PS1dE9 transgenic mice. J Biomed Sci. 2016. PMID: 27350344
- [2] Nagano M, et al. Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomed Res. 2010. PMID: 20834180
- [3] Vigna L, et al. Hericium erinaceus Improves Mood and Sleep Disorders in Patients Affected by Overweight or Obesity. Evid Based Complement Alternat Med. 2019. PMID: 31118969
- [4] Limanaqi F, et al. Potential Antidepressant Effects of Scutellaria baicalensis, Hericium erinaceus and Rhodiola rosea. Antioxidants. 2020. PMID: 32178272
- [5] Menon A, et al. Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review. Front Nutr. 2025. PMID: 40959699
Disclaimer: This article is for informational purposes only and does not constitute medical advice. The content on SafeShrooms.com is not intended to diagnose, treat, cure, or prevent any disease or health condition. Always consult a qualified healthcare professional before starting any new supplement.
